Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Expert Insight on Important Clinical Trial Data From ESGO 2021 Informing Treatment for Ovarian Cancer and Endometrial Cancers

The 2021 SGO Virtual Annual Meeting, 19-25 March 2021, in Seattle, Washington, USA; The 2021 ASCO Annual Meeting, 4-8 June 2021, in Chicago, Illinois, USA; The 2021 IGCS Meeting, 30 August - 2 September, in Rome, Italy; The ESMO 2021 Annual Congress, 17-21 September 2021, in Paris, France; The 2021 ESGO Conference, 23-26 October 2021, in Prague, Czech Republic
In this podcast episode, listen to Nicole Concin, MD, PhD, as she highlights important clinical trial data for ovarian and endometrial cancers presented at the ESGO 2021 annual meeting.
Nicole Concin, MD, PhD
Released: November 23, 2021

In this episode, Nicole Concin, MD, PhD, highlights key data for endometrial and ovarian cancers presented at the ESGO 2021 annual meeting, including:

  • Pooled data from 7 phase III clinical trials evaluating surgical outcomes as prognostic factors for patients with high-grade serous, low-grade serous, mucinous, and clear cell ovarian cancer
  • Update from the phase I GARNET study in patients with advanced/recurrent mismatch repair deficient/microsatellite instability‒high or proficient/stable endometrial cancer
  • Results from the TOTEM trial evaluating the impact of minimalist vs intensive follow-up on health-related quality of life and cost for patients with endometrial cancer

Information on this Educational Activity


Nicole Concin, MD, PhD

Department of Gynaecology and Obstetrics
Medical University Innsbruck
Innsbruck, Austria
Consultant in Gynaecological Oncology
Department of Gynaecology and Gynaecologocial Oncology
KEM Evang. Kliniken Essen-Mitte
Essen, Germany

Nicole Concin, MD, PhD, has disclosed that she has received consulting fees from Akesobio, AstraZeneca, Ensai, eTheRNA immunotherapies NV, GlaxoSmithKline, Mersana, and Seattle Genetics and other financial or material support from Amgen, Genmab, MSD, and Roche.

Program Medium

This program has been made available online.


This educational activity is supported by an educational grant from

Related Content

In this commentary from Clinical Care Options (CCO), Asim V. Farooq, MD and Joann Kang, MD, provide guidance on monitoring and mitigating ocular toxicities associated with antibody-drug conjugates

Asim V. Farooq, MD Joann Kang, MD Released: January 20, 2022

Prof Nicole Concin, MD, PhD, shares her thoughts on the application of new clinical data for ovarian and endometrial cancers in Europe in this clinical commentary from Clinical Care Options (CCO)

Nicole Concin, MD, PhD Released: December 7, 2021

Clinical commentary with Colleen Bohnenkamp, PharmD, BCOP, BCPS, and Dane Fritzsche, PharmD, BCOP, on application of new clinical data for ovarian and endometrial cancers in Europe, from Clinical Care Options (CCO)

Colleen Bohnenkamp, PharmD, BCOP, BCPS Dane Fritzsche, PharmD, BCOP Released: December 7, 2021

Downloadable short slideset from CCO on recognizing and managing ocular toxicities associated with antibody–drug conjugates.

Asim V. Farooq, MD Joann Kang, MD Paul G. Richardson, MD Released: November 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings